A Randomized Study of Atezolizumab vs Placebo administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly Diagnosed Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (GOG3015) (YO39523)

A Randomized Study of Atezolizumab vs Placebo administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly Diagnosed Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (GOG3015) (YO39523)

Trial Category:
Gynecologic
Phase
III
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE

This study is looking at whether adding the drug Atezolizumab to the treatment of Paclitaxel, Carboplatin, and Bevacizumab (Current common treatment) will add long term benefit to patients who are newly diagnosed with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.  Patients are "randomized" on this study.  This means a computer tells the study team which treatment you will receive.  Neither the patient or the physician can choose the treatment assignment.  The purpose of Randomized trials is to equally study both treatment options using the same criteria in order to identify if one treatment may be superior to another treatment.  It is not known whether the addition of the drug Atezolizumab will produce superior outcomes than the current treatment.  

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members